{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:22:53Z","timestamp":1785410573607,"version":"3.56.0"},"reference-count":72,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"crossref","award":["256322"],"award-info":[{"award-number":["256322"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"crossref"}]},{"award":["256322"],"award-info":[{"award-number":["256322"]}],"id":[{"id":"https:\/\/ror.org\/024d6js02","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Background: Breast cancer treatment is often based on multimodal approaches in locally advanced stages typically including neoadjuvant chemotherapy (NACT). There are limited options for the assessment of prognosis and early identification of future non-responders, which has led to the study of circulating cell-free DNA (cfDNA) and its tumor-derived subset, circulating tumor DNA (ctDNA), for potential use as non-invasive markers for prediction of response and prognosis associated with NACT. Methods: We have evaluated the literature on approaches to the use of cfDNA and\/or ctDNA as potential biomarkers for NACT. Results: Out of 142 references going back to 2010, we found there were 87 original research reports, 39 reviews, 10 clinical trial reports and six case reports. A detailed analysis revealed several distinctive ways that markers were evaluated in a clinical setting. The original studies have focused on cfDNA, especially cfDNA integrity, whereby increasing integrity levels correlate with tumor shrinkage, reductions in proliferation markers, and hence indicate a better prognosis. Similarly, epigenetic alterations have shown promising results, with methylated ctDNA levels decreasing in responders. Further studies demonstrated the utility of ctDNA persistence through the NACT as strongly associated with shorter disease-free and overall survival. The most recent approaches of longitudinal ctDNA monitoring were found to be valuable for early identification of patients at high risk for post-operative recurrence. Conclusions: It should be noted that while most reports indicate the important role of circulating DNA in the assessment of prognosis and early detection of recurrence, there is currently only a limited utility in the prediction of eventual neoadjuvant therapy outcomes.<\/jats:p>","DOI":"10.3390\/curroncol33080450","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:11:56Z","timestamp":1785168716000},"page":"450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of the Use of Circulating DNA as a Biomarker in Neoadjuvant Therapy of Breast Cancer"],"prefix":"10.3390","volume":"33","author":[{"given":"Jannis","family":"Tornikidis","sequence":"first","affiliation":[{"name":"Department of Surgery, Motol University Hospital, 2nd Faculty of Medicine, Charles University, 150 00 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Pazdirek","sequence":"additional","affiliation":[{"name":"Department of Surgery, Motol University Hospital, 2nd Faculty of Medicine, Charles University, 150 00 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Stolz","sequence":"additional","affiliation":[{"name":"Department of Surgery, Motol University Hospital, 2nd Faculty of Medicine, Charles University, 150 00 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0615-6116","authenticated-orcid":false,"given":"Marek","family":"Minarik","sequence":"additional","affiliation":[{"name":"Department of Surgery, Motol University Hospital, 2nd Faculty of Medicine, Charles University, 150 00 Prague, Czech Republic"},{"name":"Department of Analytical Chemistry, Faculty of Science, Charles University, 128 00 Prague, Czech Republic"},{"name":"Elphogene, s.r.o., 161 00 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lim, Y.X., Lim, Z.L., Ho, P.J., and Li, J. (2022). Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives. Cancers, 14.","DOI":"10.20944\/preprints202208.0105.v1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101062","DOI":"10.1016\/j.currproblcancer.2024.101062","article-title":"Illuminating the breast cancer survival rates among Southeast Asian women: A systematic review and meta-analysis spanning four decades","volume":"48","author":"Quang","year":"2024","journal-title":"Curr. Probl. Cancer"},{"key":"ref_4","first-page":"1178223420980377","article-title":"Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future","volume":"14","author":"Asaoka","year":"2020","journal-title":"Breast Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12703\/r\/10-2","article-title":"Recent advances in neoadjuvant therapy for breast cancer","volume":"10","author":"Potter","year":"2021","journal-title":"Fac. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3892\/ol.2014.1792","article-title":"Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer","volume":"7","author":"Kawajiri","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4137\/BMI.S6184","article-title":"Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer","volume":"5","author":"Tian","year":"2010","journal-title":"Biomark. Insights"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.18632\/oncotarget.27948","article-title":"Multigene tests for breast cancer: The physician\u2019s perspective","volume":"12","author":"Cognetti","year":"2021","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ab.2012.06.018","article-title":"Mutation-based detection and monitoring of cell-free tumor DNA in peripheralblood of cancer patients","volume":"433","author":"Benesova","year":"2013","journal-title":"Anal. Biochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","article-title":"Circulating tumor DNA as a liquid biopsy for cancer","volume":"61","author":"Heitzer","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_11","first-page":"851","article-title":"Clinical Management of Circulating Tumor DNA in Breast Cancer: Detection, Prediction, and Monitoring","volume":"17","author":"Lu","year":"2025","journal-title":"Breast Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11033-024-10198-0","article-title":"Minimal residue disease detection in early-stage breast cancer: A review","volume":"52","author":"Zhang","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/CCO.0000000000001180","article-title":"Circulating tumor DNA in early-stage triple-negative breast cancer: Clinical landscape and key open challenges","volume":"37","author":"De","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-23-2928","article-title":"Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy","volume":"30","author":"Magbanua","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00432-013-1413-5","article-title":"Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer","volume":"139","author":"Bechmann","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-014-3183-4","article-title":"NEOCENT: A randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer","volume":"148","author":"Palmieri","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s12094-017-1825-9","article-title":"Association of urinary and plasma DNA in early breast cancer patients and its links to disease relapse","volume":"20","author":"Liu","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2017.76.0033","article-title":"Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations with Survival in Metastatic Triple-Negative Breast Cancer","volume":"36","author":"Stover","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"14601","DOI":"10.1038\/s41598-020-71357-4","article-title":"Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer","volume":"10","author":"Peled","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s12282-020-01212-x","article-title":"Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: A comparison with HER2 extracellular domain protein level in serum","volume":"28","author":"Qui","year":"2021","journal-title":"Breast Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Adusei, E., Ahenkorah, J., Adu-Aryee, N.A., Adutwum-Ofosu, K.K., Tagoe, E.A., Koney, N.K., Nkansah, E., Aryee, N.A., Blay, R.M., and Hottor, B.A. (2021). Reduced Serum Circulation of Cell-Free DNA Following Chemotherapy in Breast Cancer Patients. Med. Sci., 9.","DOI":"10.3390\/medsci9020037"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5414\/CPP51059","article-title":"Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer","volume":"51","author":"Lehner","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cca.2013.07.027","article-title":"Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy","volume":"425","author":"Lehner","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.21037\/tcr.2019.08.05","article-title":"Plasma cell-free DNA integrity: A potential biomarker to monitor the response of breast cancer to neoadjuvant chemotherapy","volume":"8","author":"Wang","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2100198","DOI":"10.1200\/PO.21.00198","article-title":"Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer","volume":"6","author":"Cirmena","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-024-07366-y","article-title":"Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: A pilot study","volume":"206","author":"Giro","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.55730\/1300-0144.5834","article-title":"Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT","volume":"54","author":"Koca","year":"2024","journal-title":"Turk. J. Med. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s13277-012-0443-y","article-title":"DNA methylation of circulating DNA: A marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients","volume":"33","author":"Sharma","year":"2012","journal-title":"Tumour Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clbc.2016.06.006","article-title":"Correlation of Methylated Circulating Tumor DNA with Response to Neoadjuvant Chemotherapy in Breast Cancer Patients","volume":"17","author":"Takahashi","year":"2017","journal-title":"Clin. Breast Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1038\/s41388-018-0660-y","article-title":"Circulating cell-free DNA in breast cancer: Size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers","volume":"38","author":"Panagopoulou","year":"2019","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annonc.2019.11.014","article-title":"Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer","volume":"31","author":"Moss","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1038\/s41598-023-35362-7","article-title":"Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA","volume":"13","author":"Kahns","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100159","DOI":"10.1016\/j.jlb.2024.100159","article-title":"Comprehensive analysis of plasma methylome reveals distinct patterns of methylation changes between responders and non-responders to neoadjuvant chemotherapy in breast cancer","volume":"6","author":"Ravera","year":"2024","journal-title":"J. Liq. Biopsy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100168","DOI":"10.1016\/j.jlb.2024.100168","article-title":"Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer","volume":"6","author":"Shan","year":"2024","journal-title":"J. Liq. Biopsy"},{"key":"ref_35","first-page":"11782234241288671","article-title":"Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis with Neoadjuvant Chemotherapy: HARMONY Study","volume":"18","author":"Tokura","year":"2024","journal-title":"Breast Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105286","DOI":"10.1016\/j.esmoop.2025.105286","article-title":"Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer","volume":"10","author":"Elliott","year":"2025","journal-title":"ESMO Open"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-025-02170-y","article-title":"\u039dovel methylation biomarkers in liquid biopsy and classifying biosignatures for the clinical management of breast cancer","volume":"28","author":"Panagopoulou","year":"2026","journal-title":"Breast Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-023-00512-7","article-title":"ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease","volume":"9","author":"Stecklein","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Li, C., He, Q., Liang, H., Cheng, B., Li, J., Xiong, S., Zhao, Y., Guo, M., Liu, Z., and He, J. (2020). Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00290"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12\u2013158 Randomized Clinical Trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.5306\/wjco.v12.i8.702","article-title":"PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report","volume":"12","author":"Valencia","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1007\/s12010-022-03946-0","article-title":"Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer","volume":"194","author":"Wei","year":"2022","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djad080","article-title":"Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer","volume":"115","author":"Kim","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41523-023-00607-1","article-title":"Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment","volume":"10","author":"Zaikova","year":"2024","journal-title":"npj Breast Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Du, T., Yuan, Y., Sun, S., Gao, Z., and Li, X. (2024). Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: A multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA. BMC Women\u2019s Health, 24.","DOI":"10.1186\/s12905-024-03486-1"},{"key":"ref_46","first-page":"302ra133","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1373\/clinchem.2016.262337","article-title":"Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer","volume":"63","author":"Riva","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"86423","DOI":"10.18632\/oncotarget.21198","article-title":"Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"a003772","DOI":"10.1101\/mcs.a003772","article-title":"Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer","volume":"5","author":"Butler","year":"2019","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-18-2521","article-title":"Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial","volume":"25","author":"Silva","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer","volume":"5","author":"Chopra","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"eaax7392","DOI":"10.1126\/scitranslmed.aax7392","article-title":"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer","volume":"11","author":"McDonald","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8132507","DOI":"10.1155\/2020\/8132507","article-title":"Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","volume":"2020","author":"Cirmena","year":"2020","journal-title":"J. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"14704","DOI":"10.1038\/s41598-020-71236-y","article-title":"Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer","volume":"10","author":"Cavallone","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4048\/jbc.2020.23.e41","article-title":"Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence","volume":"23","author":"Hao","year":"2020","journal-title":"J. Breast Cancer"},{"key":"ref_56","first-page":"PO.19.00292","article-title":"Circulating Tumor DNA Predicts the Response and Prognosis in Patients with Early Breast Cancer Receiving Neoadjuvant Chemotherapy","volume":"4","author":"Li","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.esmoop.2021.100086","article-title":"Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy","volume":"6","author":"Ortolan","year":"2021","journal-title":"ESMO Open"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10549-021-06247-y","article-title":"Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer","volume":"188","author":"Zhou","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-21-3231","article-title":"Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response","volume":"28","author":"Zhou","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e2200148","DOI":"10.1200\/PO.22.00148","article-title":"Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated with Disease Relapse","volume":"6","author":"Cailleux","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","volume":"34","author":"Parsons","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Liu, Z., Yu, B., Su, M., Yuan, C., Liu, C., Wang, X., Song, X., Li, C., Wang, F., and Ma, J. (2023). Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer. BMC Med., 21.","DOI":"10.1186\/s12916-023-03163-4"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10549-024-07508-2","article-title":"Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer","volume":"209","author":"Cutts","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41467-025-56658-4","article-title":"Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay","volume":"16","author":"Elliott","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1158\/1078-0432.CCR-24-3145","article-title":"Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer","volume":"31","author":"Ademuyiwa","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13058-025-02026-5","article-title":"Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis","volume":"27","author":"Dong","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1158\/2767-9764.CRC-24-0234","article-title":"ctDNA Detected after Neoadjuvant Therapy for HER2-Positive Breast Cancer Is Associated with Inferior Outcomes and May Inform Adjuvant Therapy","volume":"6","author":"Lin","year":"2026","journal-title":"Cancer Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12282-025-01818-z","article-title":"Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer","volume":"33","author":"Park","year":"2026","journal-title":"Breast Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"106067","DOI":"10.1016\/j.esmoop.2026.106067","article-title":"Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer","volume":"11","author":"Grinshpun","year":"2026","journal-title":"ESMO Open"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:23:20Z","timestamp":1785385400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":72,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080450"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080450","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}